A detailed history of Hsbc Holdings PLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 11,613 shares of LYEL stock, worth $12,774. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,613
Previous 18,319 36.61%
Holding current value
$12,774
Previous $26,000 38.46%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.13 - $1.88 $7,577 - $12,607
-6,706 Reduced 36.61%
11,613 $16,000
Q2 2024

Aug 12, 2024

BUY
$1.3 - $3.01 $517 - $1,197
398 Added 2.22%
18,319 $26,000
Q1 2024

May 15, 2024

BUY
$1.71 - $3.07 $30,644 - $55,017
17,921 New
17,921 $39,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.